MX341133B - Compuestos y metodos para la inhibición de hdac. - Google Patents
Compuestos y metodos para la inhibición de hdac.Info
- Publication number
- MX341133B MX341133B MX2012008280A MX2012008280A MX341133B MX 341133 B MX341133 B MX 341133B MX 2012008280 A MX2012008280 A MX 2012008280A MX 2012008280 A MX2012008280 A MX 2012008280A MX 341133 B MX341133 B MX 341133B
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- methods
- formula
- disclosed
- making
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29457510P | 2010-01-13 | 2010-01-13 | |
| PCT/US2011/021089 WO2011088181A1 (en) | 2010-01-13 | 2011-01-13 | Compounds and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012008280A MX2012008280A (es) | 2012-11-23 |
| MX341133B true MX341133B (es) | 2016-08-08 |
Family
ID=44304635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012008280A MX341133B (es) | 2010-01-13 | 2011-01-13 | Compuestos y metodos para la inhibición de hdac. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8901156B2 (enExample) |
| EP (1) | EP2533783B8 (enExample) |
| JP (1) | JP6017313B2 (enExample) |
| KR (1) | KR101781663B1 (enExample) |
| CN (1) | CN103221047B (enExample) |
| AU (1) | AU2011205283B2 (enExample) |
| BR (1) | BR112012017441B1 (enExample) |
| CA (1) | CA2787018A1 (enExample) |
| EA (1) | EA022964B1 (enExample) |
| ES (1) | ES2560627T3 (enExample) |
| IL (1) | IL220939A (enExample) |
| MX (1) | MX341133B (enExample) |
| SG (1) | SG182401A1 (enExample) |
| WO (1) | WO2011088181A1 (enExample) |
| ZA (1) | ZA201205125B (enExample) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2523664A4 (en) | 2010-01-13 | 2013-06-26 | Tempero Pharmaceuticals Inc | COMPOUNDS AND METHODS |
| EA201490228A1 (ru) * | 2011-07-08 | 2014-08-29 | Новартис Аг | Новые производные трифторметилоксадиазола и их применение для лечения заболевания |
| WO2013066833A1 (en) * | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods to inhibit histone deacetylase (hdac) enzymes |
| WO2013066835A2 (en) * | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| KR20140097459A (ko) | 2011-11-28 | 2014-08-06 | 노파르티스 아게 | 신규 트리플루오로메틸-옥사디아졸 유도체 및 질환의 치료에서의 그의 용도 |
| WO2013113773A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| WO2013113791A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| WO2013113716A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| WO2013113863A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| JP2015508752A (ja) | 2012-02-03 | 2015-03-23 | ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ | 殺菌性ピリミジン化合物 |
| WO2013113776A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| WO2013113778A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| WO2013113720A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| NZ704666A (en) * | 2012-08-23 | 2018-05-25 | Alios Biopharma Inc | Compounds for the treatment of paramoxyvirus viral infections |
| CN102826985B (zh) * | 2012-09-18 | 2015-08-19 | 厦门大学 | 一种1-(3,4,5-三羟基)苯基-1-烷基酮的制备方法 |
| JP6423372B2 (ja) | 2013-02-28 | 2018-11-14 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 強力なｒｏｃｋ１およびｒｏｃｋ２阻害剤としてのフェニルピラゾール誘導体 |
| TW201444798A (zh) | 2013-02-28 | 2014-12-01 | 必治妥美雅史谷比公司 | 作爲強效ｒｏｃｋ１及ｒｏｃｋ２抑制劑之苯基吡唑衍生物 |
| CN103214327A (zh) * | 2013-03-22 | 2013-07-24 | 郑州泰基鸿诺药物科技有限公司 | 一种芳香环或芳杂环三氟甲基酮化合物及其制备方法 |
| HK1225716A1 (zh) * | 2013-08-21 | 2017-09-15 | Alios Biopharma, Inc. | 抗病毒化合物 |
| EP3626717A1 (en) | 2013-10-14 | 2020-03-25 | Eisai R&D Management Co., Ltd. | Selectively substituted quinoline compounds |
| US9663486B2 (en) | 2013-10-14 | 2017-05-30 | Eisai R&D Management Co., Ltd. | Selectively substituted quinoline compounds |
| PL226024B1 (pl) * | 2013-10-23 | 2017-06-30 | Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną | Zastosowanie N-[2-[4-(4-metoksyfenylo)-1,3-tiazol-2-ilo]etylo]- -2-okso-2,5,6,7-tetrahydrocyklopenta[b] pirydyno-3-karboksyamidu |
| EP3151669B1 (en) | 2014-06-06 | 2020-10-28 | Basf Se | Use of substituted oxadiazoles for combating phytopathogenic fungi |
| EP3187497A4 (en) * | 2014-08-26 | 2018-02-07 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| EA201790502A1 (ru) | 2014-09-16 | 2017-10-31 | Селджен Квонтисел Рисёрч, Инк. | Ингибиторы гистоновых диметилаз |
| US9896436B2 (en) | 2014-09-16 | 2018-02-20 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| CN104262281A (zh) * | 2014-10-16 | 2015-01-07 | 湖南华腾制药有限公司 | 一种2-溴-4(4-乙氧基苯基)恶唑的制备方法 |
| WO2016065583A1 (en) * | 2014-10-30 | 2016-05-06 | Merck Sharp & Dohme Corp. | Oxazole orexin receptor antagonists |
| SI3587417T1 (sl) | 2014-12-09 | 2022-04-29 | Bayer Ag | 1,3-tiazol-2-il substituirani benzamidi |
| US10183937B2 (en) * | 2014-12-09 | 2019-01-22 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides |
| US10183934B2 (en) | 2015-02-02 | 2019-01-22 | Forma Therapeutics, Inc. | Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors |
| SG11201706146UA (en) | 2015-02-02 | 2017-08-30 | Forma Therapeutics Inc | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors |
| WO2016164770A1 (en) | 2015-04-10 | 2016-10-13 | Bioresponse, L.L.C. | Self-emulsifying formulations of dim-related indoles |
| WO2016179550A1 (en) | 2015-05-07 | 2016-11-10 | Chdi Foundation, Inc. | Histone deacetylase inhibitors and compositions and methods of use thereof |
| EP3291810B1 (en) | 2015-05-07 | 2022-08-10 | CHDI Foundation, Inc. | Histone deacetylase inhibitors and compositions and methods of use thereof |
| EP3327019A4 (en) | 2015-07-17 | 2019-04-03 | Takeda Pharmaceutical Company Limited | HETEROCYCLIC CONNECTION |
| ES2793014T3 (es) | 2015-07-17 | 2020-11-12 | Takeda Pharmaceuticals Co | Derivados de oxadiazol útiles como inhibidores de HDAC |
| RU2700696C2 (ru) * | 2015-07-27 | 2019-09-19 | Чонг Кун Данг Фармасьютикал Корп. | 1,3,4,-оксадизоламидное производное соединение в качестве ингибитора гистондеацетилазы 6 и содержащая его фармацевтическая композиция |
| NZ736432A (en) | 2015-07-27 | 2019-01-25 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| WO2017018803A1 (en) * | 2015-07-27 | 2017-02-02 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| HUE057544T2 (hu) | 2015-08-04 | 2022-05-28 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazol-származék vegyületek mint hiszton deacetiláz 6 inhibitorok, és ezeket tartalmazó gyógyszerkészítmények |
| WO2017033946A1 (ja) | 2015-08-25 | 2017-03-02 | 武田薬品工業株式会社 | 複素環化合物 |
| EP3356358B1 (en) | 2015-10-02 | 2020-05-06 | Syngenta Participations AG | Microbiocidal oxadiazole derivatives |
| US10501425B2 (en) | 2015-10-02 | 2019-12-10 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
| RU2695133C1 (ru) * | 2015-10-12 | 2019-07-22 | Чонг Кун Данг Фармасьютикал Корп. | Производные оксадиазоламина в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция |
| EP3167716A1 (en) | 2015-11-10 | 2017-05-17 | Basf Se | Substituted oxadiazoles for combating phytopathogenic fungi |
| WO2017081309A1 (en) | 2015-11-13 | 2017-05-18 | Basf Se | Substituted oxadiazoles for combating phytopathogenic fungi |
| AR106679A1 (es) | 2015-11-13 | 2018-02-07 | Basf Se | Oxadiazoles sustituidos para combatir hongos fitopatógenos |
| BR112018008449B1 (pt) | 2015-11-19 | 2021-07-06 | Basf Se | Compostos de fórmula i, mistura, composição agroquímica e método para combater fungos nocivos fitopatogênicos |
| MX2018006474A (es) | 2015-12-02 | 2018-08-01 | Syngenta Participations Ag | Derivados de oxadiazol microbicidas. |
| PE20181022A1 (es) | 2015-12-03 | 2018-06-27 | Basf Se | Oxadiazoles sustituidos para combatir hongos fitopatogenos |
| US10750742B2 (en) | 2015-12-22 | 2020-08-25 | Syngenta Participations Ag | Pesticidally active pyrazole derivatives |
| UY37062A (es) | 2016-01-08 | 2017-08-31 | Syngenta Participations Ag | Derivados de aryl oxadiazol fungicidas |
| CN105503716A (zh) * | 2016-01-30 | 2016-04-20 | 天长市淳峰精细材料合成厂 | 一种2,6-二氰基吡啶的制备方法 |
| JP6970680B2 (ja) * | 2016-03-15 | 2021-11-24 | セルジーン クオンティセル リサーチ，インク． | ヒストンデメチラーゼ阻害剤 |
| BR112018069412B1 (pt) | 2016-03-24 | 2022-09-20 | Syngenta Participations Ag | Compostos derivados de oxadiazol microbiocidas, composição agroquímica, método de controle ou prevenção de infestação de plantas úteis por microrganismos fitopatogênicos e uso do referido composto |
| CA3020532A1 (en) | 2016-04-11 | 2017-10-19 | Basf Se | Substituted oxadiazoles for combating phytopathogenic fungi |
| WO2017218950A1 (en) | 2016-06-17 | 2017-12-21 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors |
| WO2017222950A1 (en) * | 2016-06-23 | 2017-12-28 | Merck Sharp & Dohme Corp. | 3-heterocyclyl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors |
| US11066396B2 (en) | 2016-06-23 | 2021-07-20 | Merck Sharp & Dohme Corp. | 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors |
| AR109304A1 (es) | 2016-08-10 | 2018-11-21 | Sumitomo Chemical Co | Compuesto de oxadiazol y su uso |
| WO2018057933A1 (en) * | 2016-09-22 | 2018-03-29 | The Regents Of The University Of Colorado, A Body Corporate | Compounds, compositions, and methods for reducing oxidative stress in cardiomyocytes |
| US10357493B2 (en) | 2017-03-10 | 2019-07-23 | Selenity Therapeutics (Bermuda), Ltd. | Metalloenzyme inhibitor compounds |
| JP7146797B2 (ja) | 2017-03-31 | 2022-10-04 | シンジェンタ パーティシペーションズ アーゲー | 殺菌性組成物 |
| US10435399B2 (en) | 2017-07-31 | 2019-10-08 | Takeda Pharmaceutical Company Limited | HDAC6 inhibitory heterocyclic compound |
| CN112351981A (zh) | 2018-06-29 | 2021-02-09 | 先正达农作物保护股份公司 | 杀微生物的噁二唑衍生物 |
| US12161639B2 (en) | 2018-07-17 | 2024-12-10 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating PACS1 and PACS2 syndromes |
| KR102316234B1 (ko) | 2018-07-26 | 2021-10-22 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| US12010995B2 (en) | 2018-08-08 | 2024-06-18 | Nihon Nohyaku Co., Ltd. | Oxadiazoline compounds or salts thereof, agrohorticultural fungicides containing the compounds, and methods of using the same |
| AR118673A1 (es) | 2019-04-18 | 2021-10-20 | Syngenta Crop Protection Ag | Procedimiento para la preparación de derivados de oxadiazol microbiocidas |
| EP3976602A4 (en) | 2019-05-31 | 2023-05-31 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-OXADIAZOLE HOMOPHTHALIMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE-6 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF |
| CN110526878A (zh) * | 2019-09-16 | 2019-12-03 | 成都睿智化学研究有限公司 | 一种2-(噁唑基)乙胺的制备方法 |
| TWI882012B (zh) | 2019-09-27 | 2025-05-01 | 日商武田藥品工業股份有限公司 | 雜環化合物 |
| CN114616231A (zh) | 2019-11-07 | 2022-06-10 | 日本农药株式会社 | 噁二唑啉化合物或其盐类及含有该化合物的农园艺用杀菌剂、以及其使用方法 |
| CN112194620B (zh) * | 2020-12-04 | 2021-02-26 | 苏州开元民生科技股份有限公司 | 一种2-乙基-4-氰基吡啶的制备方法 |
| MA63501B1 (fr) | 2021-06-14 | 2024-07-31 | Scorpion Therapeutics, Inc. | Dérivés d'urée pouvant être utilisés pour traiter le cancer |
| CN116253730B (zh) * | 2023-03-06 | 2025-09-02 | 浙江大学 | 一种靶向降解hdac7蛋白的protac类化合物及其制备方法与应用 |
| CN116354897B (zh) * | 2023-03-31 | 2024-10-15 | 华东师范大学 | 一种取代的1，2，4-三氮唑、吡啶及嘧啶衍生物及其在药物中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5523312A (en) | 1994-09-27 | 1996-06-04 | Sterling Winthrop Inc. | Antipicornaviral agents |
| ATE361316T1 (de) | 1999-09-08 | 2007-05-15 | Sloan Kettering Inst Cancer | Kristallstruktur einer deacetylase und deren inhibitoren |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| TWI319387B (en) | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
| CA2590811C (en) * | 2004-12-10 | 2013-07-30 | Barbara Attenni | Heterocycle derivatives as histone deacetylase (hdac) inhibitors |
| EP1863756A1 (en) * | 2005-03-24 | 2007-12-12 | Janssen Pharmaceutica N.V. | Biaryl derived amide modulators of vanilloid vr1 receptor |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| EP2523664A4 (en) | 2010-01-13 | 2013-06-26 | Tempero Pharmaceuticals Inc | COMPOUNDS AND METHODS |
| US20120322827A1 (en) | 2010-01-13 | 2012-12-20 | Erkan Baloglu | Compounds and methods |
| WO2013006408A1 (en) | 2011-07-01 | 2013-01-10 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
| EA201490228A1 (ru) | 2011-07-08 | 2014-08-29 | Новартис Аг | Новые производные трифторметилоксадиазола и их применение для лечения заболевания |
-
2011
- 2011-01-13 WO PCT/US2011/021089 patent/WO2011088181A1/en not_active Ceased
- 2011-01-13 AU AU2011205283A patent/AU2011205283B2/en not_active Ceased
- 2011-01-13 MX MX2012008280A patent/MX341133B/es active IP Right Grant
- 2011-01-13 ES ES11733353.4T patent/ES2560627T3/es active Active
- 2011-01-13 CA CA2787018A patent/CA2787018A1/en not_active Abandoned
- 2011-01-13 EA EA201290638A patent/EA022964B1/ru not_active IP Right Cessation
- 2011-01-13 US US13/522,044 patent/US8901156B2/en not_active Expired - Fee Related
- 2011-01-13 KR KR1020127021121A patent/KR101781663B1/ko not_active Expired - Fee Related
- 2011-01-13 SG SG2012050076A patent/SG182401A1/en unknown
- 2011-01-13 EP EP11733353.4A patent/EP2533783B8/en active Active
- 2011-01-13 CN CN201180013827.0A patent/CN103221047B/zh not_active Expired - Fee Related
- 2011-01-13 JP JP2012549064A patent/JP6017313B2/ja not_active Expired - Fee Related
- 2011-01-13 BR BR112012017441-0A patent/BR112012017441B1/pt not_active IP Right Cessation
-
2012
- 2012-07-10 ZA ZA2012/05125A patent/ZA201205125B/en unknown
- 2012-07-12 IL IL220939A patent/IL220939A/en not_active IP Right Cessation
-
2014
- 2014-10-22 US US14/520,633 patent/US20150038534A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL220939A (en) | 2016-11-30 |
| MX2012008280A (es) | 2012-11-23 |
| EP2533783B8 (en) | 2015-12-16 |
| US20130059883A1 (en) | 2013-03-07 |
| EA022964B1 (ru) | 2016-03-31 |
| EA201290638A1 (ru) | 2013-02-28 |
| AU2011205283A1 (en) | 2012-08-02 |
| BR112012017441B1 (pt) | 2019-11-19 |
| US20150038534A1 (en) | 2015-02-05 |
| IL220939A0 (en) | 2012-09-24 |
| EP2533783B1 (en) | 2015-11-04 |
| ZA201205125B (en) | 2013-03-27 |
| EP2533783A1 (en) | 2012-12-19 |
| CA2787018A1 (en) | 2011-07-21 |
| WO2011088181A1 (en) | 2011-07-21 |
| SG182401A1 (en) | 2012-08-30 |
| CN103221047A (zh) | 2013-07-24 |
| WO2011088181A9 (en) | 2013-01-31 |
| EP2533783A4 (en) | 2013-07-17 |
| US8901156B2 (en) | 2014-12-02 |
| AU2011205283B2 (en) | 2014-07-10 |
| KR101781663B1 (ko) | 2017-09-25 |
| JP6017313B2 (ja) | 2016-10-26 |
| KR20130036093A (ko) | 2013-04-10 |
| ES2560627T3 (es) | 2016-02-22 |
| CN103221047B (zh) | 2014-12-17 |
| JP2013517278A (ja) | 2013-05-16 |
| BR112012017441A2 (pt) | 2016-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX341133B (es) | Compuestos y metodos para la inhibición de hdac. | |
| MX2012008141A (es) | Compuestos y metodos. | |
| IN2015DN00960A (enExample) | ||
| EP2566477A4 (en) | AMINO-QUINOLINES AS KINASE INHIBITORS | |
| MX341456B (es) | Amino-quinolinas como inhibidores de cinasa. | |
| PH12014502697B1 (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
| MX2014014531A (es) | Derivados de aminoquinazolina y piridopirimidina. | |
| TN2012000575A1 (en) | Compositions and methods for modulating the wnt signaling pathway | |
| MY163187A (en) | Novel imidazo-oxazine compound or salt thereof | |
| UA107791C2 (en) | Pesticidal compositions | |
| MY171055A (en) | 3,5-disubstituted alkynylbenzene compound and salt thereof | |
| MY169043A (en) | New dihydroquinoline-2-one derivatives | |
| MY169267A (en) | New aryl-quinoline derivatives | |
| IN2012DN01342A (enExample) | ||
| MX349373B (es) | Nuevos derivados de pirazina. | |
| MX2012014796A (es) | Proceso para preparar 4-hidroxipiridinas. | |
| GB201305247D0 (en) | Amide Compounds | |
| MX346980B (es) | Nuevos compuestos de hexahidrociclopentapirrolona, hexahidropirrolopirrolona, octahidropirrolopiridinona y octahidropiridinona. | |
| IN2014DN10669A (enExample) | ||
| MX2012005155A (es) | Compuestos de quinazolina. | |
| MX2013009388A (es) | Nuevos compuestos de azaespirodecanona como inhibidores de lipasa sensible a hormonas (hsl). | |
| MX2013009386A (es) | Nuevos compuestos de azaespirodecanona. | |
| MX2013013021A (es) | Nuevos compuestos de hexahidropirroloimidazolona. | |
| IN2012DN00346A (enExample) | ||
| IN2013MN01107A (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |